Nimes

• EPO-TRAUMA Recruiting
  2023-506081-31-00 5 2022-03-29 Traumatic Injury
• Efficacy and safety of Sodium Oxybate in reducing alcohol consumption and maintaining abstinence in alcohol-dependent subjects with high and … Recruiting
  2023-506990-37-00 5 2021-07-13 Alcohol addiction
• Add-on buprenorphine at analgesic doses for the treatment of severe suicidal ideas during a major depressive episode Recruiting
  2024-512445-17-00 4 2021-07-01 mental disorders
• Neonatal hypoxic ischemic encephalopathy : safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOST … Recruiting
  2024-516421-30-00 4 2020-02-05 Neonatal hypoxic-ischaemic encephalopathy
• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 5 2019-06-05 Middle or low locally advanced resectable rectal carcinoma
• Opioid-Free Analgesia In Intensive Care Unit (OFICU) Ended recruitment
  2024-517770-14-00 6 2025-11-24 Intubation
• A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat … Ended recruitment
  2024-513015-27-00 5 2025-01-09 Moderately to Severely Active Ulcerative Colitis (UC)
• ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO … Ended recruitment
  2023-504594-20-00 1 2025-01-06 Healthy volunteers
• Evaluation of the effect of a single dose of psilocybin on neural correlates of cognitive control in patients with CNEP (psychogenic nonepil … Ended recruitment
  2023-509679-17-00 4 2024-11-05 psychogenic non-epileptic seizures
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended recruitment
  2023-504839-40-00 5 2024-03-18 Episodic Migraine
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended recruitment
  2023-507187-39-00 5 2023-03-23 High-Risk Non-muscle-invasive Bladder Cancer
• A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely … Ended recruitment
  2023-504719-34-00 5 2023-02-21 Moderate to Severly Active Ulcerative Colitis
• Assessment of Flecainide to Lower the patent foramen Ovale closure risk of Atrial arrhythmia or Tachycardia Ended recruitment
  2024-513324-42-00 5 2022-03-23 Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardia
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509372-41-00 5 2022-01-30 Multiple Sclerosis
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA … Ended recruitment
  2024-513252-15-00 4 2021-01-28 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended recruitment
  2022-501645-70-00 5 2020-11-25 Crohns Disease
• A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung … Ended recruitment
  2024-511185-37-00 6 2020-11-03 Completely resected stage I or IIA non-squamous non-small cell lung ca
• Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr … Ended recruitment
  2024-515331-30-00 7 2020-10-30 Primary Central Nervous System Lymphoma (PCNSL)
• A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su … Ended recruitment
  2024-514088-25-00 5 2019-10-07 Multiple Myeloma
• study of the efficacy of treatment with AG-221 in patients with myelodysplastic syndrome and mutation IDH2 Ended recruitment
  2024-513858-29-01 4 2019-02-06 myelodysplastic syndrome with IDH2 mutated

Showing 49–72 of 88 trials